Danish drugs and bioindustrial company Novo Nordisk AS is to build a pharmaceutical plant in Koriyama, Japan. The company's decision to build a new plant "that will significantly exceed the capacity of the old Atsugi plant," says Roger Moore, president of Novo Nordisk Japan, "reflects the increasing demand for Novo Nordisk's products in Japan."
The site will be the home of a 7,400 square meter facility for packaging, quality control and warehousing for a wide range of the company's products, including insulin preparations, ie NovoPen, NovoLet and Nordiject injection systems, Glucagon Novo (used to treat hypoglycemia as well as for motility inhibition in connection with gastrointestinal radiography and endoscopy), and the human growth hormone Norditropin.
Novo Nordisk's total investment in the new plant could amount to about 4.7 billion yen ($47.5 million). Construction will start early next year, with completion scheduled for 1996. When fully operational, the facility will employ around 70 people. The activities of the Atsugi plant will eventually be transferred to Koriyama.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze